Sign In
Buy NBTX
$38.39
-1.77 (-4.41%)
At Close: Jul 31, 2026
Voting Rights and Shares Capital of the Company
04:15pm, Tuesday, 17'th Feb 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NASDAQ:NBTX) Shares Gap Up Following Analyst Upgrade
01:36am, Tuesday, 10'th Feb 2026
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report)'s stock price gapped up before the market opened on Monday after Guggenheim raised their price target on the stock from $8.00 to $26.00
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Rating of “Moderate Buy” from Brokerages
04:31am, Sunday, 08'th Feb 2026
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com repo
Voting Rights and Shares Capital of the Company
04:15pm, Tuesday, 13'th Jan 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NASDAQ:NBTX) Trading Up 3.3% – Time to Buy?
02:55am, Sunday, 28'th Dec 2025
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) shares were up 3.3% during trading on Friday. The stock traded as high as $23.68 and last traded at $23.39. Approximately 2,809 shares
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Hold” from Brokerages
03:30am, Saturday, 20'th Dec 2025
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have earned an average rating of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat reports.
Voting Rights and Shares Capital of the Company
04:15pm, Wednesday, 17'th Dec 2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
02:30am, Monday, 15'th Dec 2025
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
04:15pm, Monday, 24'th Nov 2025
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
10:29am, Monday, 24'th Nov 2025
It has grown wildly, and it could keep growing.
PARIS and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-ba
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
04:15pm, Monday, 03'rd Nov 2025
PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic app
PARIS and CAMBRIDGE, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-ba
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
04:15pm, Wednesday, 01'st Oct 2025
Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 st
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
04:15pm, Tuesday, 30'th Sep 2025
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic ap
